Australia markets close in 23 minutes

NeuroScientific Biopharmaceuticals Limited (NSB.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.07000.0000 (0.00%)
As of 01:48PM AEDT. Market open.

NeuroScientific Biopharmaceuticals Limited

85 Forrest Street
Suite 5
Cottesloe, WA 6011
61 8 6382 1805

Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO & Company Sec.119.16kN/AN/A
Mr. Stephen CarterChief Exec. OfficerN/AN/AN/A
Dougal ThringChief Operating OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.

Corporate governance

NeuroScientific Biopharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.